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however it was not signiﬁcantly associated with mayor and life threatening bleeding
events. Ticagrelor was not signiﬁcantly associated with any king of bleeding
compared to clopidogrel.
TCT-505
Optimal Dual Antiplatelet Therapy Duration after Lower Extremity Peripheral
Artery Intervention
Avantika Banerjee1, Karan Sarode2, Atif Mohammad2, Seth Jelinek3,
Karthik D. Mekala3, Purav Mody4, Swagata Das1, Donald Williams1,
Osvaldo Gigliotti3, Anand Prasad5, Michael Luna6, Tayo Addo6,
Emmanouil Brilakis2, Subhash Banerjee2
1VA North Texas Health Care System, Dallas, TX, 2UT Southwestern Medical Center
and VA North Texas Health Care System, Dallas, TX, Dallas, TX, 3Seton Medical
Center, Austin, TX, 4University of Texas Southwestern Medical Center, Dallas, TX,
5University of Texas Health Science Center at San Antonio, San Antonio, TX, 6UT
Southwestern Medical Center, Dallas, TX
Background: Although dual antiplatelet therapy (DAPT) is commonly prescribed
after lower extremity peripheral artery interventions, its optimal duration has not yet
been established.
Methods: We analyzed 494 limb interventions from 367 patients between July 2005
and May 2014 enrolled in the multicenter Excellence in Peripheral Artery Disease
(XLPAD) registry (NCT01904851) for the primary endpoint (death, myocardial
infarction, coronary or limb revascularization, unplanned amputation and surgical
revascularization) over a 12 month period based on the duration of prescribed or
received DAPT.
Results: DAPT was prescribed following 92.3% procedures, with 228 (50%) each in
3 months and >3 months duration. After adjusting for ankle brachial index,
Rutherford category, and cardiovascular risk factors, primary endpoint free survival
was similar between prescription groups (hazard ratio [HR]: 0.99, 95% conﬁdence
interval [CI]: 0.55-1.78; p¼0.998). 50.9% actually received 3 months DAPT while
49.1% received >3 months, with no differences in primary endpoint free survival
(HR: 1.16, 95% CI: 0.69-1.95; p¼0.567). Importantly, >3 DAPT duration was more
often prescribed to patients with prior coronary artery disease (p< 0.001, Figure 1).Conclusions: Experience across operators suggests equipoise in the selection of
DAPT duration after peripheral artery intervention, with longer prescription duration
selected for patients with preexisting coronary artery disease.
TCT-506
Comparison Of Ticagrelor and Prasugrel In STEMI-Patients: 30-Day Mortality
After Primary PCI
Barbara Bergmans1, Eva Nieuweboer2, Pim A. Tonino3
1Catharina Hospital, Eindhoven, Noord-Brabant, 2Catharina Hospital, Eindhoven,
Noord Brabant, 3Catharina hospital, Eindhoven, Netherlands
Background: Recent trials indicate that both Ticagrelor and Prasugrel are superior to
Clopidogrel in preventing cardiovascular events. However, as to date, no trials have
been conducted comparing these drugs directly. We compared 30-day mortality in
patients with STEMI receiving Ticagrelor or Prasugrel.
Methods: This retrospective study included 1069 consecutive STEMI-patients in the
Catharina Hospital, Eindhoven area, The Netherlands. From April 2012 until April
2013, patients received Prasugrel loading (60mg) and maintenance dose (patients
older than 75 years or weighing less than 60 kg were given Clopidogrel). From April
2013 onward, they received Ticagrelor loading (180mg) and maintenance dose. Death
was deﬁned as death from any cause within 30 days after primary PCI. Binary logistic
regression was used for comparison of anti-platelet strategies.
Results: No patients were lost to follow-up. In the Ticagrelor group 28 out of 524
patients (5.3%) died within 30 days after PCI, as compared to 21 out of 545 patients
(3.9%) in the ’Prasugrel/Clopidogrel’ group (OR, 1.4;95% CI, 0.79 to 2.5; p¼0.2).JACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/ReAnalysis of the Ticagrelor group compared with Prasugrel alone ((n¼305) by
excluding Clopidogrel-treated patients) showed a 2.3% mortality in the Prasugrel
group (OR, 2.4;95% CI, 1.04 to 5.57; p¼0.04). However, after adjusting for age, no
signiﬁcant difference was found between Ticagrelor and Prasugrel treated patients
(OR, 1.5; 95% CI 0.61 to 3.6; p¼0.4).Conclusions: We found no signiﬁcant difference in 30-day mortality in STEMI-
patients treated with Ticagrelor or Prasugrel in a large, retrospective, single-centre
study.Renal and Mesenteric Intervention
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Background: Renal Artery Aneurysms (RAAs) can be surgically treated but due to
high risk, endovascular procedures have been proposed (coils, graft...). All these
techniques have some drawbacks, potential complications and contraindications. We
propose a new technique: the Multilayer Flow Modulator (MFM*), a self expandable.
Methods: This MFM* is a 3D braided tube made of several interconnected layers
without any covering. Our earliest tests, in vitro (theorical simulation computerized
Fluid dynamics, Molecular Modelization) & in vivo. demonstrate that this MFM*
reduces the velocity in the aneurismal sac up to 90% by modifying the hemodynamic
conditions.. A saccular aneurysm (A.) without collateral branch will thrombose
quickly. If a collateral branch is present the ﬂow is directed towards this branch
leading to shrinkage of the aneurysm. In fusiform A. the ﬂow is laminated, the vor-
texes eliminated, eliminating the risk of rupture. Animal experiments show excellent
results. Moreover, as demonstrated in animal and human studies this MFM preserves
the collateral branches and increases the ﬂow in them, allowing the possibility to cover
any artery without compromising the ﬂow.
Results: 8 RAAs (right:5, left: 3) in 8 pts (male: 3) mean age 58 y. treated with MFM*
6 pts had atheromatous disease, 2 a ﬁbromuscular dysplasia. One pt had a solitary
kidney. All these pts had hypertension. 10 MFM*(⌀: 5 to 6 mm, length 30 to 60 mm)
loaded in a 6 F sheath implanted by femoral approach through 8 F guiding catheter.
These stents covered major renal branches without compromising the ﬂow. Technical
success: 100%. No complications. Immediately: important reduction of the velocities
inside the aneurismal sac. 6 to 36 month follow up will be presented. All aneurysms
thrombosed with diameter reduction in some pts. The thrombosis could take several
weeks depending on the importance of collateral branches. All the side branches
remain patent.nal and Mesenteric Intervention B149
